Consists of ambroxol, levocetirizine, paracetamol, phenylephrine
Ambroxol (Lenex) indications
For use Max Pidek Pharmaceuticals as monotherapy and in combination with clavulanic acid: an infectious-inflammatory diseases caused by susceptible microorganisms, including bronchitis, pneumonia, tonsillitis, pyelonephritis, urethritis, infections of the gastrointestinal tract, gynecological infections, infections of the skin and soft tissue, listeria, leptospirosis, gonorrhea.
For use Max Pidek Pharmaceuticals in combination with metronidazole: chronic gastritis in acute, peptic ulcer and duodenal ulcer in acute, associated with Helicobacter Pylori.
Uses of Ambroxol (Lenex) in details
Ambroxol (Lenex) is used to treat certain diseases of the respiratory tract and to relieve cough associated with thickened mucous.
Ambroxol (Lenex) description
Each retard capsule contains Ambroxol (Lenex) hydrochloride 75 mg.
Each tablet contains Ambroxol (Lenex) hydrochloride 30 mg.
Each 5 mL of syrup contains Ambroxol (Lenex) hydrochloride 15 or 30 mg.
Each mL of syrup (infant drops) contains Ambroxol (Lenex) hydrochloride 6 mg.
Ambroxol (Lenex) hydrochloride is trans-4-[(2-amino-3,5-dibromo-benzyl)amino] cyclohexanol hydrochloride.
It also contains the following excipients: Retard Capsules: Crospovidone collidon CL, carnauba wax, stearyl alcohol, magnesium stearate.
Tablets: Lactose, maize starch, colloidal silica, magnesium stearate.
Syrup: Purified water, sorbitol liquid, glycerol 85%, woodberry aroma (15 mg only), strawberry aroma (30 mg only), hydroxyethylcellulose, benzoic acid, acesulfame potassium, vanilla aroma.
Infant Drops: Hydroxyethylcellulose, sorbitol solution, glycerol 85%, sodium saccharin, pharma flavors, menthol, benzoic acid, propylene glycol.
Ambroxol (Lenex) dosage
Sustained-Release Capsule: Adults and Children >12 years: 1 cap once daily after meal with plenty of liquid (sufficient supply of liquid supports the expectorant effect of Ambroxol (Lenex)).
Ambroxol (Lenex) SR capsule is not suitable for children <12 years.
Tablet: Adults and Children >12 years: 1 tab thrice daily for the first 2-3 days and then 1 tab twice daily or ½ tab thrice daily. Children 6-12 years: ½ tab 2-3 times a day.
Syrup: Adults and Children >12 years: 10 mL thrice daily during the first 2-3 days, them 10 mL twice daily or 5 mL thrice daily. Children 6-12 years: 5 mL 2-3 times a day; 2-5 years: 2.5 mL 3 times a day; <2 years: 2.5 mL 2 times a day.
DS Syrup: Adults and Children >12 years: 5 mL thrice daily for 2-3 days then 5 mL twice daily for 2.5 mL thrice daily. Children 6-12 years: 2.5 mL 2-3 times a day.
Infant Drops: Children 13-24 months: 1.25 mL twice a day; 7-12 months: 1 mL twice a day; ≤6 months: 0.5 mL twice a day.
Ambroxol (Lenex) interactions
Amoxicillin may decrease the effectiveness of contraceptives for oral administration.
With the simultaneous use of Max Pidek Pharmaceuticals with bactericidal antibiotics (including aminoglycosides, cephalosporins, cycloserine, vancomycin, rifampicin) appears synergies; with bacteriostatic antibiotic (including macrolides, chloramphenicol, lincosamides, tetracyclines, sulphonamide) - antagonism.
Amoxicillin increases the effects of indirect anticoagulants inhibiting intestinal microflora, reduces the synthesis of vitamin K and prothrombin index.
Amoxicillin reduces the effect of drugs, in the process of metabolism that produce PABA.
Probenecid, diuretics, allopurinol, phenylbutazone, NSAIDs decrease the tubular secretion of amoxicillin, which can be accompanied by an increase in its concentration in blood plasma.
Antacids, glucosamine, laxatives, aminoglycosides, slow down and reduce, and ascorbic acid increases the absorption of amoxicillin.
With the combined use of amoxicillin and clavulanic acid pharmacokinetics of both components unchanged.
Ambroxol (Lenex) side effects
Allergic reactions: urticaria, erythema, edema Quincke, rhinitis, conjunctivitis, rarely - fever, joint pain, eosinophilia, in rare cases - anaphylactic shock.
Side effects associated with chemotherapy effect: possible development of super-infection (particularly in patients with chronic diseases or low resistance of the organism).
With prolonged use at high doses: dizziness, ataxia, confusion, depression, peripheral neuropathy, seizures.
Mostly when Max Pidek Pharmaceuticals used in combination with metronidazole: nausea, vomiting, anorexia, diarrhea, constipation, epigastric pain, glossitis, stomatitis; rarely - hepatitis, pseudomembranous colitis, allergic reactions (urticaria, angioedema), interstitial nephritis, a violation of hematopoiesis.
Mostly when Max Pidek Pharmaceuticals used in combination with clavulanic acid: cholestatic jaundice, hepatitis, rarely - erythema multiforme, toxic epidermal necrolysis, exfoliative dermatitis.
Ambroxol (Lenex) contraindications
Hypersensitivity to Ambroxol (Lenex) hydrochloride or to any other excipients of Ambroxol (Lenex).
In case of rare hereditary conditions that may be incompatible with an excipient of Ambroxol (Lenex), the use of Ambroxol (Lenex) is contraindicated.
What is Levocetirizine (Lenex)?
Levocetirizine (Lenex) is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Levocetirizine (Lenex) is used to treat symptoms of year-round (perennial) allergies in adults and children who are at least 6 months old. It is also used to treat symptoms of seasonal allergies in adults and children who are at least 2 years old.
Levocetirizine (Lenex) is also used to treat itching and swelling caused by chronic urticaria (hives) in adults and children who are at least 6 months old.
Levocetirizine (Lenex) may also be used for purposes not listed in this medication guide.
Levocetirizine (Lenex) indications
Seasonal Allergic Rhinitis
Levocetirizine (Lenex) dihydrochloride is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older.
Perennial Allergic Rhinitis
Levocetirizine (Lenex) dihydrochloride is indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 months of age and older.
Chronic Idiopathic Urticaria
Levocetirizine (Lenex) dihydrochloride is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.
How should I use Levocetirizine (Lenex)?
Use Levocetirizine (Lenex) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Levocetirizine (Lenex) by mouth with or without food. Take it in the evening unless your doctor tells you otherwise.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- If you miss a dose of Levocetirizine (Lenex), take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Levocetirizine (Lenex).
Uses of Levocetirizine (Lenex) in details
Levocetirizine (Lenex) is used to treat symptoms of allergic conditions such as allergic fever (hay fever), year-round allergies like dust or pet allergies and chronic nettle rash.
Levocetirizine (Lenex) description
Levocetirizine (Lenex) is a third-generation non-sedative antihistamine indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It was developed from the second-generation antihistamine cetirizine. Levocetirizine (Lenex) is the R-enantiomer of the cetirizine racemate. Levocetirizine (Lenex) is an inverse agonist that decreases activity at histamine H1 receptors. This in turn prevents the release of other allergy chemicals and increased blood supply to the area, and provides relief from the typical symptoms of hay fever. It does not prevent the actual release of histamine from mast cells. Levocetirizine (Lenex) was approved by the United States Food and Drug Administration on May 25, 2007 and is marketed under the brand Levocetirizine (Lenex)® by sanofi-aventis U.S. LLC.
Levocetirizine (Lenex) dosage
Levocetirizine (Lenex) Dosage
Generic name: Levocetirizine (Lenex) DIHYDROCHLORIDE 5mg
Dosage form: tablet, film coated, oral solution
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Levocetirizine (Lenex) is available as 2.5 mg/5 mL (0.5 mg/mL) oral solution and as 5 mg breakable (scored) tablets, allowing for the administration of 2.5 mg, if needed. Levocetirizine (Lenex) can be taken without regard to food consumption.
Adults and Children 12 Years of Age and Older
The recommended dose of Levocetirizine (Lenex) is 5 mg (1 tablet or 2 teaspoons [10 mL] oral solution) once daily in the evening. Some patients may be adequately controlled by 2.5 mg (1/2 tablet or 1 teaspoon [5 mL] oral solution) once daily in the evening.
Children 6 to 11 Years of Age
The recommended dose of Levocetirizine (Lenex) is 2.5 mg (1/2 tablet or 1 teaspoon [5 mL] oral solution) once daily in the evening. The 2.5 mg dose should not be exceeded because the systemic exposure with 5 mg is approximately twice that of adults.
Children 6 months to 5 Years of Age
The recommended initial dose of Levocetirizine (Lenex) is 1.25 mg (1/2 teaspoon oral solution) [2.5mL] once daily in the evening. The 1.25 mg once daily dose should not be exceeded based on comparable exposure to adults receiving 5 mg.
Dose Adjustment for Renal and Hepatic Impairment
In adults and children 12 years of age and older with:
- Mild renal impairment (creatinine clearance [CL CR] = 50-80 mL/min): a dose of 2.5 mg once daily is recommended;
- Moderate renal impairment (CL CR = 30-50 mL/min): a dose of 2.5 mg once every other day is recommended;
- Severe renal impairment (CL CR = 10-30 mL/min): a dose of 2.5 mg twice weekly (administered once every 3-4 days) is recommended;
- End-stage renal disease patients (CL CR < 10 mL/min) and patients undergoing hemodialysis should not receive Levocetirizine (Lenex).
No dose adjustment is needed in patients with solely hepatic impairment. In patients with both hepatic impairment and renal impairment, adjustment of the dose is recommended.
More about Levocetirizine (Lenex) (Levocetirizine (Lenex))
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 82 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Levocetirizine (Lenex)
- Levocetirizine (Lenex) solution
- Levocetirizine (Lenex) (Advanced Reading)
Professional resources
- Levocetirizine (Lenex) (AHFS Monograph)
- Levocetirizine (Lenex) (FDA)
Related treatment guides
- Urticaria
- Allergic Rhinitis
- Allergies
Levocetirizine (Lenex) interactions
See also:
What other drugs will affect Levocetirizine (Lenex)?
Drug interaction studies have been performed with racemic cetirizine.
Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline and Pseudoephedrine: Pharmacokinetic interaction studies performed with racemic cetirizine demonstrated that cetirizine did not interact with antipyrine, pseudoephedrine, erythromycin, azithromycin, ketoconazole and cimetidine. There was a small decrease (approximately 16%) in the clearance of cetirizine caused by theophylline 400 mg dose. It is possible that higher theophylline doses could have a greater effect. Interactions with Other Medicaments:
The extent of absorption of Levocetirizine (Lenex) is not reduced with food, although the rate of absorption is decreased.
In sensitive patients the simultaneous administration of cetirizine or Levocetirizine (Lenex) and alcohol or other CNS depressants, may have effects on the central nervous system, although it has been shown that the racemate cetirizine does not potentiate the effect of alcohol.
Levocetirizine (Lenex) side effects
See also:
What are the possible side effects of Levocetirizine (Lenex)?
Use of Levocetirizine (Lenex) has been associated with somnolence, fatigue, asthenia, and urinary retention.
Clinical Trials Experience
The safety data described below reflect exposure to Levocetirizine (Lenex) in 2708 patients with seasonal or perennial allergic rhinitis or chronic idiopathic urticaria in 14 controlled clinical trials of 1 week to 6 months duration.
The short-term (exposure up to 6 weeks) safety data for adults and adolescents are based upon eight clinical trials in which 1896 patients (825 males and 1071 females aged 12 years and older) were treated with Levocetirizine (Lenex) 2.5, 5, or 10 mg once daily in the evening.
The short-term safety data from pediatric patients are based upon two clinical trials in which 243 children with seasonal or perennial allergic rhinitis (162 males and 81 females 6 to 12 years of age) were treated with Levocetirizine (Lenex) 5 mg once daily for 4 to 6 weeks, one clinical trial in which 114 children (65 males and 49 females 1 to 5 years of age) with allergic rhinitis or chronic idiopathic urticaria were treated with Levocetirizine (Lenex) 1.25 mg twice daily for 2 weeks, and one clinical trial in which 45 children (28 males and 17 females 6 to 11 months of age) with symptoms of allergic rhinitis or chronic urticaria were treated with Levocetirizine (Lenex) 1.25 mg once daily for 2 weeks.
The long-term (exposure of 4 or 6 months) safety data in adults and adolescents are based upon two clinical trials in which 428 patients (190 males and 238 females) with allergic rhinitis were exposed to treatment with Levocetirizine (Lenex) 5 mg once daily. Long term safety data are also available from an 18-month trial in 255 Levocetirizine (Lenex)-treated subjects 12-24 months of age.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.
Adults and Adolescents 12 years of Age and Older
In studies up to 6 weeks in duration, the mean age of the adult and adolescent patients was 32 years, 44% of the patients were men and 56% were women, and the large majority (more than 90%) was Caucasian.
In these trials 43% and 42% of the subjects in the Levocetirizine (Lenex) 2.5 mg and 5 mg groups, respectively, had at least one adverse event compared to 43% in the placebo group.
In placebo-controlled trials of 1-6 weeks in duration, the most common adverse reactions were somnolence, nasopharyngitis, fatigue, dry mouth, and pharyngitis, and most were mild to moderate in intensity. Somnolence with Levocetirizine (Lenex) showed dose ordering between tested doses of 2.5, 5 and 10 mg and was the most common adverse reaction leading to discontinuation (0.5%).
Table 1 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 12 years and older exposed to Levocetirizine (Lenex) 2.5 mg or 5 mg in eight placebo-controlled clinical trials and that were more common with Levocetirizine (Lenex) than placebo.
Table 1 : Adverse Reactions Reported in ≥ 2%* of Subjects Aged 12 Years and Older Exposed to Levocetirizine (Lenex) 2.5 mg or 5 mg Once Daily in Placebo-Controlled Clinical Trials 1-6 Weeks in Duration
| Adverse Reactions | Levocetirizine (Lenex) 2.5 mg (n = 421) | Levocetirizine (Lenex) 5 mg (n = 1070) | Placebo (n = 912) |
| Somnolence | 22 (5%) | 61 (6%) | 16 (2%) |
| Nasopharyngitis | 25 (6%) | 40 (4%) | 28 (3%) |
| Fatigue | 5 (1%) | 46 (4%) | 20 (2%) |
| Dry Mouth | 12 (3%) | 26 (2%) | 11 (1%) |
| Pharyngitis | 10 (2%) | 12 (1%) | 9 (1%) |
| *Rounded to the closest unit percentage |
Additional adverse reactions of medical significance observed at a higher incidence than in placebo in adults and adolescents aged 12 years and older exposed to Levocetirizine (Lenex) are syncope (0.2%) and weight increased (0.5%).
Pediatric Patients 6 To 12 Years Of Age
A total of 243 pediatric patients 6 to 12 years of age received Levocetirizine (Lenex) 5 mg once daily in two short-term placebo controlled double-blind trials. The mean age of the patients was 9.8 years, 79 (32%) were 6 to 8 years of age, and 50% were Caucasian. Table 2 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 6 to 12 years exposed to Levocetirizine (Lenex) 5 mg in placebo-controlled clinical trials and that were more common with Levocetirizine (Lenex) than placebo.
Table 2 : Adverse Reactions Reported in ≥ 2%* of Subjects Aged 6-12 Years Exposed to Levocetirizine (Lenex) 5 mg Once Daily in Placebo-Controlled Clinical Trials 4 and 6 Weeks in Duration
| Adverse Reactions | Levocetirizine (Lenex) 5 mg (n = 243) | Placebo (n = 240) |
| Pyrexia | 10 (4%) | 5 (2%) |
| Cough | 8 (3%) | 2 ( < 1%) |
| Somnolence | 7 (3%) | 1 ( < 1%) |
| Epistaxis | 6 (2%) | 1 ( < 1%) |
| *Rounded to the closest unit percentage |
Pediatric Patients 1 To 5 Years Of Age
A total of 114 pediatric patients 1 to 5 years of age received Levocetirizine (Lenex) 1.25 mg twice daily in a two week placebo-controlled double-blind safety trial. The mean age of the patients was 3.8 years, 32% were 1 to 2 years of age, 71% were Caucasian and 18% were Black. Table 3 lists adverse reactions that were reported in greater than or equal to 2% of subjects aged 1 to 5 years exposed to Levocetirizine (Lenex) 1.25 mg twice daily in the placebo-controlled safety trial and that were more common with Levocetirizine (Lenex) than placebo.
Table 3 : Adverse Reactions Reported in ≥ 2%* of Subjects Aged 1-5 Years Exposed to Levocetirizine (Lenex) 1.25 mg Twice Daily in a 2-Week Placebo-Controlled Clinical Trial
| Adverse Reactions | Levocetirizine (Lenex) 1.25 mg Twice Daily (n = 114) | Placebo (n = 59) |
| Pyrexia | 5 (4%) | 1 (2%) |
| Diarrhea | 4 (4%) | 2 (3%) |
| Vomiting | 4 (4%) | 2 (3%) |
| Otitis Media | 3 (3%) | 0 (0%) |
| *Rounded to the closest unit percentage |
Pediatric Patients 6 To 11 Months Of Age
A total of 45 pediatric patients 6 to 11 months of age received Levocetirizine (Lenex) 1.25 mg once daily in a two week placebo-controlled double-blind safety trial. The mean age of the patients was 9 months, 51% were Caucasian and 31% were Black. Adverse reactions that were reported in more than 1 subject (i.e. greater than or equal to 3% of subjects) aged 6 to 11 months exposed to Levocetirizine (Lenex) 1.25 mg once daily in the placebo-controlled safety trial and that were more common with Levocetirizine (Lenex) than placebo included diarrhea and constipation which were reported in 6 (13%) and 1 (4%) and 3 (7%) and 1 (4%) children in the Levocetirizine (Lenex) and placebo-treated groups, respectively.
Long-Term Clinical Trials Experience
In two controlled clinical trials, 428 patients (190 males and 238 females) aged 12 years and older were treated with Levocetirizine (Lenex) 5 mg once daily for 4 or 6 months. The patient characteristics and the safety profile were similar to that seen in the short-term studies. Ten (2.3%) patients treated with Levocetirizine (Lenex) discontinued because of somnolence, fatigue or asthenia compared to 2 ( < 1%) in the placebo group.
There are no long term clinical trials in children below 12 years of age with allergic rhinitis or chronic idiopathic urticaria.
Laboratory Test Abnormalities
Elevations of blood bilirubin and transaminases were reported in < 1% of patients in the clinical trials. The elevations were transient and did not lead to discontinuation in any patient.
Post-Marketing Experience
In addition to the adverse reactions reported during clinical trials and listed above, adverse reactions have also been identified during post-approval use of Levocetirizine (Lenex). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions of hypersensitivity and anaphylaxis, increased appetite, angioedema, fixed drug eruption, pruritus, rash and urticaria, convulsion, paraesthesia, dizziness, tremor, dysgeusia, vertigo, movement disorders (including dystonia and oculogyric crisis), aggression and agitation, hallucinations, depression, insomnia, suicidal ideation, visual disturbances, blurred vision, palpitations, tachycardia, dyspnea, nausea, vomiting, hepatitis, dysuria, urinary retention, myalgia, arthralgia, and edema have been reported.
Besides these reactions reported under treatment with Levocetirizine (Lenex), other potentially severe adverse events have been reported from the post-marketing experience with cetirizine. Since Levocetirizine (Lenex) is the principal pharmacologically active component of cetirizine, one should take into account the fact that the following adverse events could also potentially occur under treatment with Levocetirizine (Lenex): orofacial dyskinesia, severe hypotension, cholestasis, glomerulonephritis, still birth, tic, myoclonus, and extrapyramidal symptoms.
Levocetirizine (Lenex) contraindications
See also:
What is the most important information I should know about Levocetirizine (Lenex)?
You should not use this medication if you are allergic to Levocetirizine (Lenex) or cetirizine (Zyrtec).
Do not take Levocetirizine (Lenex) if you have end-stage kidney disease or if you are on dialysis. Any child younger than 12 years old with kidney disease should not take Levocetirizine (Lenex).
Before taking Levocetirizine (Lenex), tell your doctor if you have liver disease, kidney disease, or gallbladder problems.
It is very important not to give a child more than the prescribed dose of this medication. A child's body absorbs twice as much of the same dose size of Levocetirizine (Lenex) as an adult's body.
Call your doctor if your symptoms do not improve, if they get worse, or if you also have a fever.
What is Paracetamol (Lenex)?
Paracetamol (Lenex) (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of Paracetamol (Lenex) of is not known.
Paracetamol (Lenex) is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint.
Paracetamol (Lenex) may also be used for other purposes not listed in this medication guide.
Paracetamol (Lenex) indications
For systemic use of Paracetamol (Lenex) Sante Naturelle: prevention and treatment of hypo- and avitaminosis of vitamin C; providing increased need for vitamin C during growth, pregnancy, lactation, with heavy loads, fatigue and during recovery after prolonged severe illness; in winter with an increased risk of infectious diseases.
For intravaginal use: chronic or recurrent vaginitis (bacterial vaginosis, nonspecific vaginitis) caused by the anaerobic flora (due to changes in pH of the vagina) in order to normalize disturbed vaginal microflora.
How should I use Paracetamol (Lenex)?
Use Paracetamol (Lenex) exactly as directed on the label, or as prescribed by your doctor.
Do not use more of this medication than is recommended. An overdose of Paracetamol (Lenex) can cause serious harm. The maximum amount for adults is 1 gram (1000 mg) per dose and 4 grams (4000 mg) per day. Using more Paracetamol (Lenex) could cause damage to your liver. If you drink more than three alcoholic beverages per day, talk to your doctor before taking Paracetamol (Lenex) and never use more than 2 grams (2000 mg) per day. If you are treating a child, use a pediatric form of Paracetamol (Lenex). Carefully follow the dosing directions on the medicine label. Do not give the medication to a child younger than 2 years old without the advice of a doctor.
Measure the liquid form of Paracetamol (Lenex) with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one. You may need to shake the liquid before each use. Follow the directions on the medicine label.
The Paracetamol (Lenex) chewable tablet must be chewed thoroughly before you swallow it.
Make sure your hands are dry when handling the Paracetamol (Lenex) disintegrating tablet. Place the tablet on your tongue. It will begin to dissolve right away. Do not swallow the tablet whole. Allow it to dissolve in your mouth without chewing.
To use the Paracetamol (Lenex) effervescent granules, dissolve one packet of the granules in at least 4 ounces of water. Stir this mixture and drink all of it right away. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.
Do not take a Paracetamol (Lenex) rectal suppository by mouth. It is for use only in your rectum. Wash your hands before and after inserting the suppository.
Try to empty your bowel and bladder just before using the Paracetamol (Lenex) suppository. Remove the outer wrapper from the suppository before inserting it. Avoid handling the suppository too long or it will melt in your hands.
For best results from the suppository, lie down and insert the suppository pointed tip first into the rectum. Hold in the suppository for a few minutes. It will melt quickly once inserted and you should feel little or no discomfort while holding it in. Avoid using the bathroom just after inserting the suppository.
Stop using Paracetamol (Lenex) and call your doctor if:
-
you still have a fever after 3 days of use;
-
you still have pain after 7 days of use (or 5 days if treating a child);
-
you have a skin rash, ongoing headache, or any redness or swelling; or
-
if your symptoms get worse, or if you have any new symptoms.
Urine glucose tests may produce false results while you are taking Paracetamol (Lenex). Talk to your doctor if you are diabetic and you notice changes in your glucose levels during treatment.
Store Paracetamol (Lenex) at room temperature away from heat and moisture. The rectal suppositories can be stored at room temperature or in the refrigerator.
Uses of Paracetamol (Lenex) in details
This drug is used to treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches and pains) and to reduce fever.
How to use Paracetamol (Lenex)
Take this product by mouth as directed. Follow all directions on the product package. If you are uncertain about any of the information, consult your doctor or pharmacist.
There are many brands and forms of acetaminophen available. Read the dosing instructions carefully for each product because the amount of acetaminophen may be different between products. Do not take more acetaminophen than recommended.
If you are giving acetaminophen to a child, be sure you use a product that is meant for children. Use your child's weight to find the right dose on the product package. If you don't know your child's weight, you can use their age.
For suspensions, shake the medication well before each dose. Some liquids do not need to be shaken before use. Follow all directions on the product package. Measure the liquid medication with the provided dose-measuring spoon/dropper/syringe to make sure you have the correct dose. Do not use a household spoon.
For rapidly-dissolving tablets, chew or allow to dissolve on the tongue, then swallow with or without water. For chewable tablets, chew thoroughly before swallowing.
Do not crush or chew extended-release tablets. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split the tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.
For effervescent tablets, dissolve the dose in the recommended amount of water, then drink.
Pain medications work best if they are used as the first signs of pain occur. If you wait until the symptoms have worsened, the medication may not work as well.
Do not take this medication for fever for more than 3 days unless directed by your doctor. For adults, do not take this product for pain for more than 10 days (5 days in children) unless directed by your doctor. If the child has a sore throat (especially with high fever, headache, or nausea/vomiting), consult the doctor promptly.
Tell your doctor if your condition persists or worsens or if you develop new symptoms. If you think you may have a serious medical problem, get medical help right away.
Paracetamol (Lenex) description
Paracetamol (Lenex) is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms. Paracetamol (Lenex) exists as small alkaline deliquescent crystals with a saline tasteacinol was introduced to medicine as a solvent for uric acid. When taken into the body the drug is partly oxidized and partly eliminated unchanged. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successfulacinol was first introduced as an anthelmintic in 1953. A large number of piperazine compounds have anthelmintic Paracetamol (Lenex). Their mode of Paracetamol (Lenex) is generally by paralysing parasites, which allows the host body to easily remove or expel the invading organism.
Paracetamol (Lenex) dosage
Usual Adult Paracetamol (Lenex) Dose for Fever:
General Dosing Guidelines: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours orally or rectally.
Paracetamol (Lenex) 500mg tablets: Two 500 mg tablets orally every 4 to 6 hours
Usual Adult Paracetamol (Lenex) Dose for Pain:
General Dosing Guidelines: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours orally or rectally.
Paracetamol (Lenex) 500mg tablets: Two 500 mg tablets orally every 4 to 6 hours
Usual Pediatric Dose for Fever:
Oral or Rectal:
<=1 month: 10 to 15 mg/kg/dose every 6 to 8 hours as needed.
>1 month to 12 years: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (Maximum: 5 doses in 24 hours)
Fever: 4 months to 9 years: Initial Dose: 30 mg/kg (Reported by one study (n=121) to be more effective in reducing fever than a 15 mg/kg maintenance dose with no difference regarding clinical tolerance.)
>=12 years: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours.
Usual Pediatric Dose for Pain:
Oral or Rectal:
<=1 month: 10 to 15 mg/kg/dose every 6 to 8 hours as needed.
>1 month to 12 years: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (Maximum: 5 doses in 24 hours)
Fever: 4 months to 9 years: Initial Dose: 30 mg/kg (Reported by one study (n=121) to be more effective in reducing fever than a 15 mg/kg maintenance dose with no difference regarding clinical tolerance.)
>=12 years: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours.
Paracetamol (Lenex) interactions
See also:
What other drugs will affect Paracetamol (Lenex)?
With the simultaneous use with inducers of microsomal liver enzymes, means having hepatotoxic effect, increasing the risk of hepatotoxic Paracetamol (Lenex) of Paracetamol (Lenex).
With the simultaneous use of anticoagulants may be slight to moderate increase in prothrombin time.
With the simultaneous use of anticholinergics may decrease absorption of Paracetamol (Lenex).
With the simultaneous use of oral contraceptives accelerated excretion of Paracetamol (Lenex) from the body and may reduce its analgesic Paracetamol (Lenex).
With the simultaneous use with urological means reduced their effectiveness.
With the simultaneous use of activated charcoal reduced bioavailability of Paracetamol (Lenex).
When Paracetamol (Lenex) applied simultaneously with diazepam may decrease excretion of diazepam.
There have been reports about the possibility of enhancing mielodepression effect of zidovudine while applying with Paracetamol (Lenex). A case of severe toxic liver injury.
Described cases of toxic effects of Paracetamol (Lenex), while the use of isoniazid.
When applied simultaneously with carbamazepine, phenytoin, phenobarbital, primidonom decreases the effectiveness of Paracetamol (Lenex), which is caused by an increase in its metabolism and excretion from the body. Cases of hepatotoxicity, while the use of Paracetamol (Lenex) and phenobarbital.
In applying cholestyramine a period of less than 1 h after administration of Paracetamol (Lenex) may decrease of its absorption.
At simultaneous application with lamotrigine moderately increased excretion of lamotrigine from the body.
With the simultaneous use of metoclopramide may increase absorption of Paracetamol (Lenex) and its increased concentration in blood plasma.
When applied simultaneously with probenecid may decrease clearance of Paracetamol (Lenex), with rifampicin, sulfinpyrazone - may increase clearance of Paracetamol (Lenex) due to increasing its metabolism in the liver.
At simultaneous application of Paracetamol (Lenex) with ethinylestradiol increases absorption of Paracetamol (Lenex) from the gut.
Enhances the effect of indirect anticoagulants (coumarin derivatives and indandione). Antipyretic and analgesic activity of caffeine increases, reduce - rifampicin, phenobarbital and alcohol (accelerated biotransformation, inducing microsomal liver enzymes).
Paracetamol (Lenex) side effects
See also:
What are the possible side effects of Paracetamol (Lenex)?
Effects due to the presence of acetylsalicylic acid.
Accidents awareness with respiratory or skin reactions (angioedema, urticaria, asthma, anaphylactic shock);
Cross hypersensitivity reactions with NSAIDs and with tartrazine;
At low doses recommended for the use of Paracetamol (Lenex), side effects of aspirin are generally limited to some irritation of the gastro-intestinal tract.
At higher doses, side effects include gastrointestinal mucosal erosions, gastric ulcer or duodenal ulcer, occult blood loss, melena.
Acetylsalicylic acid may also increase the tendency to bleeding and bleeding time (the lengthening of bleeding continues 4-6 days after stopping the drug).
It may also worsen renal function including cases of pre-existing condition (the long-term use can cause chronic kidney disease).
The signs of salicylic overdose described under.
Effects due to the presence of Paracetamol (Lenex).
At the doses and duration of recommended treatment, side effects are usually negligible, but the prolonged use of Paracetamol (Lenex) in therapeutic doses large (2-4 g per day, or 10-20 tablets Paracetamol (Lenex)) may cause the appearance chronic hepatitis. This justifies the recommendations of caution especially in patients with liver disease prior.
Very rarely, it can produce thrombocytopenia.
The acute liver toxicity in overdose massive (doses greater than 8 g of Paracetamol (Lenex)) is described in paragraph overdose.
Paracetamol (Lenex) contraindications
See also:
What is the most important information I should know about Paracetamol (Lenex)?
Paracetamol (Lenex) should not be used in patients who have previously exhibited hypersensitivity to aspirin and/or nonsteroidal antiinflammatory agents. Paracetamol (Lenex) should not be given to patients with a recent history of gastrointestinal bleeding or in patients with bleeding disorders (e.g., hemophilia).
What is Phenylephrine (Lenex)?
Phenylephrine (Lenex) (Phenylephrine (Lenex)) is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).
Phenylephrine (Lenex) is used to treat nasal and sinus congestion, or congestion of the tubes that drain fluid from your inner ears, called the eustachian (yoo-STAY-shun) tubes.
Phenylephrine (Lenex) may also be used for purposes not listed in this medication guide.
Phenylephrine (Lenex) indications
Phenylephrine (Lenex) is used for the temporary relief of stuffy nose, sinus, and ear symptoms caused by the common cold, flu, allergies, or other breathing illnesses (e.g., sinusitis, bronchitis). This medication works by decreasing swelling in the nose and ears, thereby lessening discomfort and making it easier to breathe.
Cough-and-cold products have not been shown to be safe or effective in children younger than 6 years. Therefore, do not use this product to treat cold symptoms in children younger than 6 years unless specifically directed by the doctor. Some products (such as long-acting tablets/capsules) are not recommended for use in children younger than 12 years. Ask your doctor or pharmacist for more details about using your product safely.
How should I use Phenylephrine (Lenex)?
Use Phenylephrine (Lenex) drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Phenylephrine (Lenex) drops is for use in the eye only. Avoid contact with the nose or mouth.
- To use Phenylephrine (Lenex) drops, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eye for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.
- To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including your eye. Keep the container tightly closed.
- Do not wear contact lenses while you are using Phenylephrine (Lenex) drops. Sterilize contact lenses according to the manufacturer's directions and check with your doctor before using them.
- Do not use Phenylephrine (Lenex) drops if it is brown or contains particles.
- If you miss a dose of Phenylephrine (Lenex) drops, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Phenylephrine (Lenex) drops.
Uses of Phenylephrine (Lenex) in details
Use: Labeled Indications
Hypotension/shock: Treatment of hypotension, vascular failure in shock. Note: Not recommended for routine use in the treatment of septic shock; use should be limited until more evidence demonstrating positive clinical outcomes becomes available (Rhodes 2017).
Guideline recommendations:
Cardiogenic shock: The 2017 American Heart Association (AHA) scientific statement for the Contemporary Management of Cardiogenic Shock recommends Phenylephrine (Lenex), if needed, be considered for initial vasoactive management of cardiogenic shock due to aortic stenosis, mitral stenosis, or dynamic left ventricular outflow tract (LVOT) obstruction (AHA [van Diepen 2017]).
Hypotension during anesthesia: As a vasoconstrictor in regional analgesia
Nasal congestion: As a decongestant [OTC]
Off Label Uses
Hypotension in patients with obstructive hypertrophic cardiomyopathy
Phenylephrine (Lenex) is a pure alpha1 agonist that will increase systemic vascular resistance without increasing heart rate or contractility. This is advantageous in patients with obstructive hypertrophic cardiomyopathy and hypotension since increases in both heart rate and contractility may cause the obstruction to worsen, leading to a decrease in cardiac output. Other vasopressors like dopamine, epinephrine, and norepinephrine may increase contractility and/or heart rate. Additional trials may be necessary to further define the role of Phenylephrine (Lenex) in this condition.
Based on the American Urological Association guidelines for the management of priapism, due to the low risk of cardiovascular side effects intracavernous injection of Phenylephrine (Lenex) is recommended for ischemic priapism that persists following aspiration/irrigation.
Phenylephrine (Lenex) description
Phenylephrine (Lenex) is a sympathomimetic amine that acts predominantly on α-adrenergic receptors. It is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
Phenylephrine (Lenex) dosage
Phenylephrine (Lenex) Dosage
Generic name: Phenylephrine (Lenex) HYDROCHLORIDE 10mg in 1mL
Dosage form: injection
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
General Dosage and Administration Instructions
Phenylephrine (Lenex) (Phenylephrine (Lenex) hydrochloride) Injection, 10 mg/mL must be diluted before administration as an intravenous bolus or continuous intravenous infusion to achieve the desired concentration:
- Bolus: Dilute with normal saline or 5% dextrose in water.
- Continuous infusion: Dilute with normal saline or 5% dextrose in water.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion.
During Phenylephrine (Lenex) administration:
- Correct intravascular volume depletion.
- Correct acidosis. Acidosis may reduce the effectiveness of Phenylephrine (Lenex).
Dosing for Treatment of Hypotension during Anesthesia
The following are the recommended dosages for the treatment of hypotension during anesthesia.
- The recommended initial dose is 40 to 100 mcg administered by intravenous bolus. May administer additional boluses every 1-2 minutes as needed; not to exceed a total dosage of 200 mcg.
- If blood pressure is below the target goal, start a continuous intravenous infusion with an infusion rate of 10 to 35 mcg/minute; not to exceed 200 mcg/minute.
- Adjust dosage according to the blood pressure goal.
Prepare a 100 mcg/mL Solution for Bolus
Intravenous Administration
For bolus intravenous administration, prepare a solution containing a final concentration of 100 mcg/mL of Phenylephrine (Lenex):
- Withdraw 10 mg (1 mL of 10 mg/mL) of Phenylephrine (Lenex) and dilute with 99 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.
- Withdraw an appropriate dose from the 100 mcg/mL solution prior to bolus intravenous administration.
Prepare a Solution for Continuous
Intravenous Administration
For continuous intravenous infusion, prepare a solution containing a final concentration of 20 mcg/mL of Phenylephrine (Lenex) in 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP:
- Withdraw 10 mg (1 mL of 10 mg/mL) of Phenylephrine (Lenex) and dilute with 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.
Directions for Dispensing from Pharmacy Bulk Vial
The Pharmacy Bulk Vial is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion. Each closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. The Pharmacy Bulk Vial is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Dispensing from a pharmacy bulk vial should be completed within 4 hours after the vial is penetrated.
More about Phenylephrine (Lenex) (Phenylephrine (Lenex))
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews - Add your own review/rating
Consumer resources
- Phenylephrine (Lenex)
- Phenylephrine (Lenex) (Advanced Reading)
- Other brands: Neo-Synephrine, Phenylephrine (Lenex) Congestion, Sudogest PE, Phenylephrine (Lenex) Children's Nasal Decongestant, More (9) »
Professional resources
- Phenylephrine (Lenex) (FDA)
- Phenylephrine (Lenex) Hydrochloride (AHFS Monograph)
Related treatment guides
- Hypotension
Phenylephrine (Lenex) interactions
See also:
What other drugs will affect Phenylephrine (Lenex)?
Acetaminophen: May increase the serum concentration of Phenylephrine (Lenex) (Systemic). Monitor therapy
Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Consider therapy modification
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Lenex) (Systemic). Monitor therapy
CloZAPine: May diminish the therapeutic effect of Phenylephrine (Lenex) (Systemic). Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification
Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy
Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination
FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy
Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Lenex) (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of Phenylephrine (Lenex). Use of hyaluronidase for other purposes in patients receiving Phenylephrine (Lenex) may be considered as clinically indicated. Avoid combination
Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Avoid combination
Ioflupane I 123: Phenylephrine (Lenex) (Systemic) may diminish the diagnostic effect of Ioflupane I 123. Monitor therapy
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid. Avoid combination
Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification
Propacetamol: May increase the serum concentration of Phenylephrine (Lenex) (Systemic). Management: Monitor patients closely for increased side effects of Phenylephrine (Lenex) if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies. Monitor therapy
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists. Monitor therapy
Phenylephrine (Lenex) side effects
See also:
What are the possible side effects of Phenylephrine (Lenex)?
Applies to Phenylephrine (Lenex): intravenous solution
As well as its needed effects, Phenylephrine (Lenex) (the active ingredient contained in Phenylephrine (Lenex)) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking Phenylephrine (Lenex), check with your doctor or nurse immediately:
Incidence not known:
- Blurred vision
- chest pain or discomfort
- difficult or labored breathing
- dizziness
- fainting
- fast, slow, or irregular heartbeat
- headache
- nausea or vomiting
- nervousness
- pain in the shoulders, arms, jaw, or neck
- pounding in the ears
- sweating
- tightness in the chest
- unusual tiredness
If any of the following symptoms of overdose occur while taking Phenylephrine (Lenex), get emergency help immediately:
Symptoms of overdose:
- Feeling of fullness in the head
- pounding or rapid pulse
- tingling in the arms or legs
- vomiting
Minor Side Effects
Some Phenylephrine (Lenex) side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
Incidence not known:
- Heartburn
- itching skin
- nausea
- pain in the neck
- pain or discomfort in chest, upper stomach, or throat
Phenylephrine (Lenex) contraindications
See also:
What is the most important information I should know about Phenylephrine (Lenex)?
Minims Phenylephrine (Lenex) hydrochloride should not be used in patients with severe hypertension, ventricular tachycardia, or in patients who are hypersensitive to it or to any of the components.
Active ingredient matches for Lenex:
Ambroxol/levocetirizine/paracetamol/phenylephrine in India.
| Unit description / dosage (Manufacturer) | Price, USD |
| LENEX tab 10's (Zee Lab) | $ 0.54 |
List of Lenex substitutes (brand and generic names): | |
| 1 AL TOTAL | |
| 1 AL Total Syrup (FDC Ltd) | $ 0.64 |
| 5-ZINE-A (India) | |
| 5-ZINE-A tab 10's (Soigner) | $ 0.71 |
| ACOLATE P PLUS | |
| ACOLATE PLUS | |
| ALDBEST-CF (India) | |
| ALDBEST-CF tab 10's (Vidakem) | $ 0.76 |
| ALERZILEVO-COLD (India) | |
| ALERZILEVO-COLD tab 10's (Alobiote) | |
| ambroxol/levocetirizine/paracetamol/phenylephrine (India) | |
| AVECOLD-L (India) | |
| AVECOLD-L tab 10's (Jasco) | $ 0.58 |
| CETRIL D | |
| CHESTON COLD TOTAL | |
| CURIS-PLUS (India) | |
| CURIS-PLUS tab 10's (Aprique) | |
| HISTACARE | |
| KOFCROSS-COLD (India) | |
| KOFCROSS-COLD tab 10's (Cross Berry) | $ 0.55 |
| KOFF GO PLUS | |
| LESTAR AM | |
| LESTAR-AM | |
| LEVLAR | |
| LEVOCETIRIZINE 5MG + PHENYLEPHRINE 5MG + AMBROXOL 30MG + PARACETAMOL 325MG TABLET | |
| LEVOTIZ PLUS | |
| LEVOTIZ-PLUS | |
| LEVZINE-A (India) | |
| LEVZINE-A tab 10's (Aero-Chem) | |
| LIT AP | |
| LIT-AP | |
| NASO CZ | |
| PANOMIN-TOTAL (India) | |
| PANOMIN-TOTAL tab 10's (BRD) | $ 0.51 |
| TYTO TAB (India) | |
| TYTO TAB tab 10's (TNT) | $ 0.42 |
| VOLLERGIN COUGH N COLD (India) | |
| VOLLERGIN COUGH N COLD tab 10's (BRD (Drugtech)) | $ 0.51 |
| VOZIL-P (India) | |
| VOZIL-P tab 10's (Dr Kumars) | $ 0.54 |
| ZILO-P (India) | |
| ZILO-P tab 10's (Unikind) | $ 0.48 |
References
- PubChem. "phenylephrine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- PubChem. "ambroxol". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- PubChem. "Levocetirizine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Lenex are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lenex. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet2 consumers reported age
| Users | % | ||
|---|---|---|---|
| 16-29 | 1 | 50.0% | |
| 30-45 | 1 | 50.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
